Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Palatin Technologies (PTN – Research Report) and keeping the price target at $17.00.
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Palatin Technologies’ promising developments in the treatment of obesity. The company has recently announced the clearance for a Phase 2 clinical trial for bremelanotide in combination with an FDA-approved drug for obesity, showcasing the potential for a novel therapeutic approach. The trial aims to demonstrate safety and efficacy in reducing body weight, leveraging the role of melanocortin receptor 4 (MCR4) – a key player in regulating food intake and energy balance – which could be an attractive target for new obesity treatments.
Furthermore, the synergistic effects of combining MCR4 agonists with GLP-1 therapies have shown encouraging results in preclinical studies, including significant weight loss and reduced food intake in obese rats. These findings were presented at the Peptide Therapeutics Symposium, reinforcing the scientific rationale behind the therapeutic strategy. Pantginis’s positive outlook likely reflects the potential market opportunity for effective obesity treatments and the company’s progress in advancing its clinical program, which may lead to significant value creation for investors.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Palatin Technologies (PTN) Company Description:
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
